파로스아이바이오
Financials
Valuation Metrics
파로스아이바이오's Market Cap is ₩728B. At end of 2025 it was ₩1216B. Ranked #1434 of 2,405 in KR market (top 60%), #811 of 1,627 on KOSDAQ (top 50%), #157 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 72.76B KRW | KR#1,434/2,405 Sec#157/231 |
| Net Income | -9.49B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 26.25B KRW | KR#2,345/2,405 Sec#225/231 |
| Net Assets | 9.72B KRW | KR#2,361/2,405 Sec#225/231 |
| Employees | 32 | KR#2,177/2,405 Sec#203/231 |
| Value | ||
| P/B | 7.49x | KR#2,324/2,405 Sec#206/231 |
| FCF Yield | -11.49% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -97.67% | KR#2,327/2,405 Sec#217/231 |
| ROA | -36.15% | KR#2,323/2,405 Sec#207/231 |
| Financial Health | ||
| Debt Ratio | 170.15% | KR#1,989/2,405 Sec#211/231 |
| Total Debt | 8.59B KRW | KR#1,664/2,405 Sec#152/231 |
| FCF | -8.36B KRW | KR#1,647/2,405 Sec#139/231 |
| Cash | 5.43B KRW | KR#1,967/2,405 Sec#181/231 |
| Current Ratio | 28.33x | KR#12/2,405 Sec#6/231 |
| Performance | ||
| 1Y Return | 15.28% | KR#351/2,405 Sec#21/231 |
| 1M Return | -6.64% | KR#867/2,405 Sec#81/231 |
| From 52W High | -53.63% | KR#1,332/2,405 Sec#107/231 |
| 1Y MDD | -62.91% | KR#1,614/2,405 Sec#132/231 |
| Trading | ||
| Volume | 14,194 shares | KR#1,681/2,405 Sec#164/231 |
| Trading Value | 79.2M KRW | KR#1,529/2,405 Sec#159/231 |
| Foreign Own. | 1.86% | KR#1,671/2,405 Sec#161/231 |
| Per Share | ||
| EPS | -733 KRW | KR—/2,405 Sec—/231 |
| BPS | 751 KRW | KR#2,341/2,405 Sec#220/231 |
Company Info
Pharos iBio, established in 2016 and listed on KOSDAQ in 2023 as a technology growth company, specializes in new drug development. The company operates an AI-based new drug development platform, Chemibus, integrating large-scale compound big data and multi-omics analysis technology. It focuses on innovative new drug development for rare and intractable diseases, particularly in oncology. Its flagship pipeline, PHI-101, has received orphan drug designation, aiming to accelerate development and enhance market competitiveness. Pharos iBio is headquartered in Anseong-si, Gyeonggi-do.